Cost-Effectiveness Analysis Report

Quick Analysis

Report Date:	2026-01-19 17:28:07	**Generated By:**	anonymous@ecomodel.com
Organization:	Demo	**Model Type:**	Markov 3-State

Executive Summary

ICER

€1,412,285

per QALY gained

ΔQALYS

1.287

Quality-adjusted life years

ΔCOSTS

€1,817,470

Incremental costs

CONCLUSION

Not Cost-Effective

at €30,000/QALY

Clinical and Economic Interpretation

The new treatment (Drug A) is **not cost-effective** compared to the standard treatment (Drug B) at the willingness-to-pay threshold of €30,000 per QALY gained. The incremental cost-effectiveness ratio (ICER) of €1,412,285/QALY exceeds the established threshold. While the treatment provides an additional 1.287 QALYs, the incremental cost of €1,817,470 is not justified at the current WTP threshold.

Model Parameters

Cost Parameters

Drug A Cost (€/cycle):	**€3,500**
Drug B Cost (€/cycle):	**€2,800**
Healthcare Cost - Stable (€):	**€200**
Healthcare Cost - Progression (€):	**€4,500**

Clinical Parameters

Progression Risk - Drug A:	**10.0%**
Progression Risk - Drug B:	**25.0%**
Utility - Stable:	**0.85**
Utility - Progression:	**0.50**

Model Settings

Time Horizon:	**10 years**
Discount Rate:	**3.0%**
WTP Threshold:	**€30,000/QALY**
Cycle Length:	**1 year**

Detailed Results

Comparative Effectiveness and Costs

Metric	Drug A (New)	Drug B (Standard)	Difference (Δ)
Total Costs (€)	€32,889,110	€31,071,640	€1,817,470
Total QALYs	4.933	3.646	1.287
Life Years	7.62	6.43	1.19
ICER (€/QALY)		**€1,412,285**	

Generated by EcoModel Hub - Professional HEOR Platform
This report was automatically generated on 2026-01-19 17:28:07 by anonymous@ecomodel.com
Confidential - For internal use only